- Home
- IGMS vs DHC Comparison
IGMS vs DHC Comparison
Compare IGMS & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- DHC
- Stock Information
- Founded
- IGMS 1993
- DHC 1998
- Country
- IGMS United States
- DHC United States
- Employees
- IGMS N/A
- DHC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- DHC Real Estate Investment Trusts
- Sector
- IGMS Health Care
- DHC Real Estate
- Exchange
- IGMS Nasdaq
- DHC Nasdaq
- Market Cap
- IGMS 962.1M
- DHC 855.2M
- IPO Year
- IGMS 2019
- DHC N/A
- Fundamental
- Price
- IGMS $9.47
- DHC $2.52
- Analyst Decision
- IGMS Hold
- DHC Hold
- Analyst Count
- IGMS 8
- DHC 3
- Target Price
- IGMS $14.63
- DHC $4.50
- AVG Volume (30 Days)
- IGMS 238.9K
- DHC 1.3M
- Earning Date
- IGMS 11-08-2024
- DHC 11-04-2024
- Dividend Yield
- IGMS N/A
- DHC 1.59%
- EPS Growth
- IGMS N/A
- DHC N/A
- EPS
- IGMS N/A
- DHC N/A
- Revenue
- IGMS $2,918,000.00
- DHC $1,477,343,000.00
- Revenue This Year
- IGMS $298.54
- DHC N/A
- Revenue Next Year
- IGMS N/A
- DHC $4.18
- P/E Ratio
- IGMS N/A
- DHC N/A
- Revenue Growth
- IGMS 57.64
- DHC 6.62
- 52 Week Low
- IGMS $4.72
- DHC $1.97
- 52 Week High
- IGMS $22.50
- DHC $4.24
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- DHC 28.34
- Support Level
- IGMS $10.91
- DHC $2.46
- Resistance Level
- IGMS $16.32
- DHC $2.79
- Average True Range (ATR)
- IGMS 1.53
- DHC 0.21
- MACD
- IGMS -0.79
- DHC -0.07
- Stochastic Oscillator
- IGMS 0.80
- DHC 4.80
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs.